Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

The present study aimed to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Eligibility criteria included patients with relapsed/refractory WM with any number of prior therapies. Patients rece...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Ghobrial, Irene M., Campigotto, Federico, Murphy, Timothy J., Boswell, Erica N., Banwait, Ranjit, Azab, Feda, Chuma, Stacey, Kunsman, Janet, Donovan, Amanda, Masood, Farzana, Warren, Diane, Rodig, Scott, Anderson, Kenneth C., Richardson, Paul G., Weller, Edie, Matous, Jeffrey
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2013
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578951/
https://ncbi.nlm.nih.gov/pubmed/23287861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-439307
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia